Gary Shangold
Biodexa · Biodexa Pharmaceuticals · Sponsor CMO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gary Shangold as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:14 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06950385 · Phase 3 Trial of eRapa in Patients With Familial Adenomatous PolyposisRapamycin Holdings Inc. · recruiting · Familial Adenomatous Polyposis (FAP) · study director
- Ph1NCT05324501 · A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent GlioblastomaBiodexa Pharmaceuticals · terminated · Recurrent Glioblastoma · study director
- Ph2NCT04230499 · Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active SurveillanceRapamycin Holdings Inc. · completed · Familial Adenomatous Polyposis · study director
- Ph2NCT02807363 · A Study of Pharmacokinetic/Pharmacodynamic Profile of Orally Administered Leuprolide in Healthy Female VolunteersEnteris BioPharma Inc. · completed · Endometriosis · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:14 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue.Am J Obstet Gynecol · 2000219 citationsRCR 8.0
- 213 citationsRCR 6.9
- Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data.Fertil Steril · 2002190 citationsRCR 6.8
- Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.Obstet Gynecol · 2010158 citationsRCR 6.5
- Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group.Am J Obstet Gynecol · 200099 citationsRCR 3.4
- Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women.Fertil Steril · 200289 citationsRCR 3.5
- Efficacy and safety of a transdermal contraceptive system.Obstet Gynecol · 200178 citationsRCR 2.9
- Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error.Fertil Steril · 200358 citationsRCR 2.3
- Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study.Am J Obstet Gynecol · 200244 citationsRCR 1.7
- Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.Contraception · 200142 citationsRCR 1.7